Skip to main content
. 2022 Mar 19;14(6):1574. doi: 10.3390/cancers14061574

Figure 2.

Figure 2

OS for Patients with detectable and non-detectable ctDNA at baseline (A), Post-1 (B) and, at the EOT (C).